What is Gilead Sciences's derivative liabilities - fair value?

Gilead Sciences (GILD) reported derivative liabilities - fair value of $24M in Q1 2026.

How has Gilead Sciences's derivative liabilities - fair value changed year-over-year?

Gilead Sciences's derivative liabilities - fair value decreased by 4.0% year-over-year, from $25M to $24M.

What is the long-term trend for Gilead Sciences's derivative liabilities - fair value?

Over 5 years (2020 to 2025), Gilead Sciences's derivative liabilities - fair value has grown at a 27.2% compound annual growth rate (CAGR), from $12M to $40M.

Gilead Sciences GILD Derivative Liabilities - Fair Value

Derivative Liabilities - Fair Value at other companies

ImmunityBio, Inc.IBRX

——

Merck & Co.MRK

——

BiogenBIIB

——

AbbVieABBV

——

AmgenAMGN

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

See full

Revenue$7.0B+4.4%

Gross profit$5.5B+7.6%

Operating income$2.6B+15.6%

Net income$2.0B+53.7%

EPS (diluted)$1.61+54.8%

Balance sheet

See full

Cash & equivalents$7.6B-3.8%

Total debt$22.2B-11.1%

Total equity$23.5B+22.7%

Total assets$56.3B-0.3%

Cash flow

See full

Operating cash flow$2.5B+44.8%

CapEx$117.0M+12.5%

Free cash flow$2.4B+46.8%

Valuation

See full

Market cap$153.66B+23.8%

Enterprise value$168.2B+19.7%

P/E16.7×-4.1×

P/S5.2×+0.8×

Profitability

See full

Gross margin79.4%+1.1pp

Operating margin34.9%+6.3pp

Net margin31%+10.2pp

FCF margin34.4%+0.1pp

Returns & leverage

See full

Return on equity43.2%+10.7pp

Debt / equity0.9×-0.4×

Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's derivative liabilities - fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gilead Sciences's derivative liabilities - fair value?: Gilead Sciences (GILD) reported derivative liabilities - fair value of $24M in Q1 2026.
How has Gilead Sciences's derivative liabilities - fair value changed year-over-year?: Gilead Sciences's derivative liabilities - fair value decreased by 4.0% year-over-year, from $25M to $24M.
What is the long-term trend for Gilead Sciences's derivative liabilities - fair value?: Over 5 years (2020 to 2025), Gilead Sciences's derivative liabilities - fair value has grown at a 27.2% compound annual growth rate (CAGR), from $12M to $40M.